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Summary 
Background Indolent systemic mastocytosis, including the subvariant of smouldering systemic mastocytosis, is a 
lifelong condition associated with reduced quality of life. Masitinib inhibits KIT and LYN kinases that are involved in 
indolent systemic mastocytosis pathogenesis. We aimed to assess safety and effi  cacy of masitinib versus placebo in 
severely symptomatic patients who were unresponsive to optimal symptomatic treatments. 
Methods In this randomised, double-blind, placebo-controlled, phase 3 study, we enrolled adults (aged 18–75 years) with 
indolent or smouldering systemic mastocytosis, according to WHO classifi cation or documented mastocytosis based on 
histological criteria, at 50 centres in 15 countries. We excluded patients with cutaneous or non-severe systemic 
mastocytosis after a protocol amendment. Patients were centrally randomised (1:1) to receive either oral masitinib 
(6 mg/kg per day over 24 weeks with possible extension) or matched placebo with minimisation according to severe 
symptoms. The primary endpoint was cumulative response (≥75% improvement from baseline within weeks 8–24) in 
at least one severe baseline symptom from the following: pruritus score of 9 or more, eight or more fl ushes per week, 
Hamilton Rating Scale for Depression of 19 or more, or Fatigue Impact Scale of 75 or more. We assessed treatment 
eff ect using repeated measures methodology for rare diseases via the generalised estimating equation model in a 
modifi ed intention-to-treat population, including all participants assigned to treatment minus those who withdrew due 
to a non-treatment-related cause. We assessed safety in all patients who received at least one dose of study drug. This 
trial is registered with ClinicalTrials.gov, number NCT00814073.
Findings Between Feb 19, 2009, and July 15, 2015, 135 patients were randomly assigned to masitinib (n=71) or placebo 
(n=64). By 24 weeks, masitinib was associated with a cumulative response of 18·7% in the primary endpoint 
(122·6 responses of 656·5 possible responses [weighted generalised estimating equation]) compared with 7·4% for 
placebo (48·9 of 656·5; diff erence 11·3%; odds ratio 3·6; 95% CI 1·2–10·8; p=0·0076). Frequent severe adverse 
events (>4% diff erence from placebo) were diarrhoea (eight [11%] of 70 in the masitinib group vs one [2%] of 63 in the 
placebo group), rash (four [6%] vs none), and asthenia (four [6%] vs one [2%]). The most frequent serious adverse 
events were diarrhoea (three patients [4%] vs one [2%]) and urticaria (two [3%] vs none), and no life-threatening 
toxicities occurred. One patient in the placebo group died (unrelated to study treatment).
Interpretation These study fi ndings indicate that masitinib is an eff ective and well tolerated agent for the treatment of 
severely symptomatic indolent or smouldering systemic mastocytosis. 
Funding AB Science (Paris, France).
Introduction 
Mastocytosis is a rare disease characterised by mast cell 
neoplasia and aberrant mast cell activation in various 
tissues, leading to a heterogeneous clinical presentation 
and wide variety of symptoms, such as pruritus, fl ushes, 
depression, and asthenia.1,2 Although life expectancy is 
similar to that of the general population in the relatively 
indolent variants of mastocytosis—cutaneous masto-
cytosis and indolent systemic mastocytosis, including the 
subvariant of smouldering systemic mastocytosis—
about a third of patients will experience severe symptoms 
of mast cell mediator release. A greatly increased 
occurrence and severity of such symptoms is reported in 
systemic mastocytosis when compared with cutaneous 
mastocytosis.1,2 Treatment decisions are based on the 
presence of bone marrow mast cell infi ltration and 
severity of symptoms, with the main objective being a 
sustained improvement of symptoms—ie, inhibition of 
mast cell mediator release. 
Genetic aberrations are known to be involved in the 
pathogenesis of systemic mastocytosis, predominantly 
the KIT Asp816Val (D816V) mutation, with an emerging 
understanding that a wide variety of other KIT mutations 
and mast cell regulatory genes might also be implicated.3,4 
Indeed, type and severity of symptoms are independent 
of KIT Asp816Val status.1,5,6 Masitinib is an oral tyrosine 
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kinase inhibitor that targets wild-type KIT (50% inhibitory 
concentration [IC50] 200 nM) with greater potency in vitro 
than KIT Asp816Val (IC50 5·0 μM), as well as targeting 
LYN and FYN at submicromolar concentrations.7 Wild-
type KIT, LYN, and FYN have crucial roles in the survival 
and function of mast cells, including mediator release.8,9 
Masitinib has a higher selectivity for these targeted 
kinases than other KIT inhibitors, which is likely to lower 
the risk of off -target toxicities.10,11 Phase 2 study results 
have shown its potential effi  cacy in patients with indolent 
forms of mastocytosis, regardless of their KIT Asp816Val 
status.12 
We aimed to assess the safety and effi  cacy of masitinib 
for treatment of indolent forms of systemic mastocytosis 
in patients who were unresponsive to optimal symptomatic 
treatment.
Methods 
Study design and participants 
This multicentre, parallel-group, randomised, double-
blind, placebo-controlled, phase 3 study (AB06006) was 
initiated in 2009 and conducted in 15 countries (Austria, 
Czech Republic, France, Germany, Greece, India, Italy, 
Latvia, Poland, Russia, Slovakia, Spain, Switzerland, UK, 
and USA) across 50 active centres. 
The study protocol and amendment were approved by 
the relevant institutional review boards at individual 
enrolment centres or ethics committees and conducted 
according to the Declaration of Helsinki. All patients 
provided written informed consent. 
Eligible patients were aged 18–75 years and had indolent 
or smouldering systemic mastocytosis according to the 
WHO classifi cation,13–15 or documented masto cytosis based 
on histological criteria of typical mast cell infi ltrates in a 
multifocal or diff use pattern in skin or bone marrow 
biopsy. The latter criterion encompasses all patients 
satisfying the WHO classifi cation but also selects those 
patients matching inclusion criteria from the masitinib 
phase 2 trials and AFIRMM survey.1,12 Consequently, these 
inclusion criteria are broader than the WHO classifi cation. 
To ensure consistency in the investigators’ application of 
diagnostic criteria, a blinded central document reading 
was used to verify patient eligibility for inclusion to the 
intention-to-treat (ITT) population based on a set of 
unifying criteria that encompassed the WHO classifi cation 
(appendix p 2). We did primary analysis on the ITT 
population as defi ned via this central document review. 
Additional eligibility criteria included severe symptoms of 
mast cell mediator release at baseline—pruritus score of 
9 or more determined via a patient perception 
questionnaire,1 at least eight fl ushes per week, Hamilton 
Rating Scale for Depression score of 19 or more,16 or 
Fatigue Impact Scale total score of 75 or more17—and 
documented failure of at least one symptomatic treat-
ment used at optimal dose—eg, H1-antihistamines, 
H2-antihistamines, proton pump inhibitors, sodium 
cromoglicate, antidepressants, and leukotriene antagonists 
(appendix p 12). Patients were ineligible if presenting with 
one of the following variants of mastocytosis: cutaneous 
mastocytosis (as per the amended protocol version 6.0), 
undocumented indolent systemic mastocytosis or 
smouldering systemic mastocytosis, systemic mastocytosis 
with an associated clonal haematological non-mast-cell-
lineage disease, mast cell leukaemia, or aggressive 
systemic mastocytosis; patients presenting with inadequate 
organ function defi ned via blood test levels; vulnerable 
populations such as patients with life expectancy of 
less than 6 months, known diagnosis of human 
Research in context
Evidence before this study
We searched PubMed without date restriction for reports 
pertaining to phase 2 or 3 clinical trials in indolent systemic 
mastocytosis using the search terms of “systemic 
mastocytosis” [All Fields] fi ltered for “Clinical Trial, Phase II” 
and “Clinical Trial, Phase III” [publication type]. We did not 
apply any language restrictions, but used search terms in 
English only. We identifi ed 11 previous clinical trials matching 
these search criteria, describing seven potential treatments for 
indolent systemic mastocytosis. No trial focused solely on 
indolent systemic mastocytosis, with this cohort representing 
a subgroup of overall populations that also comprised 
advanced systemic mastocytosis or cutaneous mastocytosis 
patients. All trials were open label, non-comparative (single-
arm), phase 2 studies evaluating various compounds including 
masitinib, dasatinib, everolimus, imatinib, interferon alfa, 
nilotinib, and thalidomide. Results were mixed, varying from 
potential therapeutic benefi t in select patients to no 
appreciable clinical effi  cacy.
Added value of this study
To our knowledge, this is the fi rst phase 3 prospective, randomised 
placebo-controlled study of a treatment for indolent systemic 
mastocytosis. We show a signifi cant and clinically meaningful 
treatment benefi t in this diffi  cult-to-treat population, with a 
demonstrated possibility of eff ective long-term management. 
Implications of all the available evidence
The observed positive benefi t–risk ratio supports the use of 
masitinib for patients with severely symptomatic indolent 
systemic mastocytosis. Masitinib might be a new treatment 
option for adult patients with severely symptomatic indolent 
systemic mastocytosis, including those with the subvariant of 
smouldering systemic mastocytosis, who are unresponsive to 
existing symptomatic treatments. Statistical design features 
of the study and mechanistic implications of targeting of 
non-clonal mast cells or KIT Asp816Val-independent 
signalling pathways could infl uence future trial design in 
mastocytosis.
See Online for appendix
For the statistical analysis plan, 
study protocol, and summary of 
protocol changes see http://
www.ab-science.com/pdf/
Lortholary_et_al_Lancet_
Protocol_online.pdf
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immunodefi ciency virus (HIV) infection, known cardiac 
disorders, or Eastern Cooperative Oncology Group 
performance status greater than 2; previous treatment 
with any tyrosine kinase inhibitor or treatment with any 
investigational agent within 4 weeks prior to baseline; and 
change in the symptomatic treatment of mastocytosis or 
administration of any new treatment of mastocytosis 
within 4 weeks prior to baseline (appendix p 7).
Randomisation and masking
Patients were centrally randomised to masitinib or 
placebo in a 1:1 ratio using an interactive voice response 
system and minimisation method according to the 
covariates of pruritus score, number of fl ushes per week, 
depression (measured by the Hamilton Rating Scale for 
Depression), asthenia (measured by the Fatigue Impact 
Scale), and country. Masitinib and placebo capsules were 
identical except for the active ingredient and both 
produced by Excella GmbH (Feucht, Germany), with no 
diff erence in dispensing of medication. The investigators, 
patients, data analysts, and the trial funder were blinded 
to the randomisation sequence and treatment assignment. 
Procedures
Masitinib was administered orally at 6 mg/kg per day in 
two daily doses over 24 weeks with a possibility of a 
double-blind extension period. Long-term analysis was 
done over the timeframe of weeks 8–96. Patients were 
assessed at weeks 8, 12, 16, 20, and 24 during the 24-week 
treatment period, with assessments every 12 weeks 
thereafter if entering the 2-year (96-week) extension 
period. In the event of severe toxicity related to masitinib, 
treatment interruption or dose reduction was permitted 
according to predefi ned criteria (appendix p 10). Protocol 
amendments were implemented between 3·5 years 
and 2 years prior to database unmasking, owing to an 
emergent risk of masitinib-related severe neutropenia 
and severe skin toxicity. Protocol amendment version 6.0 
aimed to modify the protocol’s benefi t–risk balance to 
identify the patient population with greatest medical 
need. The amendment introduced four key changes: 
enrolment was restricted to patients with severe baseline 
symptoms of mast cell mediator release; enrolment was 
restricted to indolent systemic mastocytosis, including 
the subvariant of smouldering systemic mastocytosis, 
because these patients exhibit greater symptom severity 
than do those with cutaneous mastocytosis;1 the threshold 
for positive treatment response was increased from 
50% to 75%, thereby enhancing the clinical relevance of 
improvement; and, as recommended in the European 
Medicines Agency (EMA) guidelines for clinical trial 
design for rare diseases, the treatment eff ect was tested 
using a repeated measures methodology—namely, 
longitudinal analysis with respect to symptoms as 
opposed to patient response rate at a single point in 
time.18 Patients with severely symptomatic systemic 
mastocytosis were defi ned as those with at least one 
severe baseline symptom of mast cell mediator release. 
Thus, only patients with indolent systemic mastocytosis 
meeting the prospectively declared inclusion criteria 
specifi ed in this amendment were included for fi nal 
analysis—ie, the ITT population.
Administration of concomitant optimal symptomatic 
treatments was allowed (appendix p 12); however, 
administration of any other kinase inhibitor, interferon 
alfa, or cladribine was not permitted during the 
study period. 
Outcomes 
The prospectively declared primary endpoint (referred to 
hereafter as 4R75%) was cumulative response in at least 
one of four severe baseline symptoms of mast cell 
mediator release (pruritus, fl ushes, depression, or 
asthenia). We defi ned response as a 75% improvement 
from baseline for any of these four symptoms. We 
defi ned cumulative response as the number of actual 
responses between weeks 8 and 24, divided by the total 
number of possible responses over the same treatment 
period (ie, with fi ve scheduled visits, each patient had a 
maximum of fi ve to 20 possible responses depending on 
the number of severe baseline symptoms). 
Secondary endpoints were cumulative response in at 
least one of three severe baseline symptoms of mast cell 
mediator release (pruritus, fl ushes, or depression) with 
response defi ned as an improvement of at least 75% from 
baseline for any of these three symptoms (referred to 
hereafter as 3R75%); cumulative response in pruritus or 
fl ushes with response defi ned as an improvement of at 
least 75% from baseline for either symptom (2R75%); 
cumulative response in pruritus alone; improvement of 
urticaria pigmentosa as measured via cumulative change 
in aff ected body surface area relative to baseline; 
disappearance of Darier’s sign; mean change of tryptase 
level at week 24 relative to baseline in patients with 
baseline tryptase level greater than 20 μg/L; cumulative 
response in micturition and stool frequency among 
patients with a baseline of eight or more per day and four 
or more per day, respectively; and quality-of-life measures 
such as the AFIRMM questionnaire (version 2). The 
safety profi le of masitinib was compared with placebo 
according to occurrence and severity of adverse events, 
regardless of causality.
Statistical analysis 
For the primary effi  cacy analysis, a cumulative total of 
1065 possible response evaluations was required to detect 
a diff erence of 12·5% in 4R75% between treatment arms 
(based on the assumption of an average 1·5 severe 
baseline symptoms per patient, over fi ve assessment 
timepoints for 142 patients, and a response of 21·0% in 
the masitinib arm vs 8·5% in the placebo arm) with a 
power of 80% and signifi cance level of 0·05 (two-sided 
log-rank test). The hypothesised response estimates were 
based on empirical knowledge from phase 2 data.
Articles
www.thelancet.com   Vol 389   February 11, 2017 615
We did primary effi  cacy analysis according to a 
modifi ed ITT population (ITT population minus those 
withdrawing for a well documented, non-treatment-
related cause—eg, no intake of drug), with results 
verifi ed via analysis on the ITT population (all eligible 
patients assigned to treatment, irrespective of actual 
treatment received), as well as other sensitivity analyses 
including the per-protocol population (modifi ed ITT 
minus those with a major protocol deviation) and 
modifi ed ITT observed cases dataset (see appendix p 2). 
The safety population comprised all ITT patients who 
received at least one dose of study medication. All main, 
sensitivity, and subgroup analyses reported here were 
prespecifi ed in the study’s statistical analysis plan prior 
to unblinding, and we did no interim analyses. We 
considered missing data as failure for primary and 
secondary analyses, did sensitivity analyses with the last 
observation carried forward or observed cases approach, 
and obtained the statistical test p value for the primary 
analysis via a re-randomisation (10 000 replicate) test.
 Figure: Trial profi le
A study amendment (August, 2013, as per protocol version 6.0) restricted enrolment to patients with severe indolent and smouldering systemic mastocytosis. 
Consequently, 87 patients with cutaneous mastocytosis or non-severe systemic mastocytosis recruited prior to this amendment were excluded from the ITT 
population. A weighted GEE model was used to provide total possible cumulative responses assessable in calculation of study endpoints. ITT and per-protocol 
populations represent sensitivity tests of primary analysis. ITT=intention-to-treat. GEE=generalised estimating equation. *Total possible cumulative responses 
assessable in calculation of the 4R75% endpoint according to GEE model. †Primary endpoint corresponds to modifi ed ITT population.
253 patients screened
111 assigned masitinib
40 excluded because of protocol amendment 47 excluded because of protocol amendment
111 assigned placebo
ITT population
   71 (657·0)* treatment ongoing
1 excluded because of no intake of drug
5 excluded because of investigator non-compliance 
 with predefined dose reduction
1 excluded because of no intake of drug
ITT population
   64 (657·0)* treatment ongoing
Safety population
   70 treatment ongoing
Modified ITT population
   67 (656·5)* treatment ongoing†
Per-protocol population
   62 (626·5)* treatment ongoing
Per-protocol population
   62 (626·5)* treatment ongoing
47 (70·1%) completed 24-week 
 period
 16 (23·9%) discontinued because 
  of adverse event
 4 (6·0%) withdrawn due to 
  insufficient efficacy
36 (53·7%) entered extension period 35 (56·5%) entered extension period
Weeks 0–96
36 (1306·0)* treatment ongoing
Weeks 0–96
35 (1306·0)* treatment ongoing
Modified ITT population
   62 (656·5)* treatment ongoing†
54 (87·1%) completed 24-week 
 period
 6 (9·7%) discontinued because 
  of adverse event
 2 (3·2%) withdrawn due to 
  insufficient efficacy
3 excluded 
    2 lost to follow-up
    1 withdrawn because of inclusion criteria violation
1 excluded 
    1 lost to follow-up
Safety population
   63 treatment ongoing
31 patients did not satisfy study eligibility criteria
222 patients enrolled and randomly
 allocated to treatment 
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We calculated the diff erence between treatment arms 
using the generalised estimating equation (GEE) 
approach (logit-link function) with treatment, symptom 
(pruritus, fl ushes, depression, and asthenia), and 
assessment schedule (weeks 8, 12, 16, 20, and 24) 
included as parameters in the model.19 This approach 
simultaneously tests for eff ect in all four outcome 
measures specifi ed in the primary endpoint, taking into 
account correlation across variables and across time so 
that valid inferences can be assured. 
This trial is registered with ClinicalTrials.gov, number 
NCT00814073.
Role of the funding source 
The funder (AB Science; Paris, France) was involved in 
the study design; data collection, analysis, and 
interpretation; and manuscript preparation and 
submission. OH, OL, and AM had full access to all the 
data in the study and fi nal responsibility to submit for 
publication.
Results
Between Feb 19, 2009, and July 15, 2015, 253 patients 
were screened, from which 222 were randomised to 
masitinib (n=111) or placebo (n=111). A protocol 
amendment in August, 2013, restricting enrolment to 
severe systemic mastocytosis resulted in exclusion of 
87 patients (40 from the masitinib arm, 47 from the 
placebo arm). As a result, the prospectively declared ITT 
population consisted of 135 patients (71 masitinib, 
64 placebo), 108 (80%) of whom satisfi ed the WHO 
classifi cation13,15 for systemic mastocytosis. The safety 
(n=133), modifi ed ITT (n=129), and per-protocol (n=124) 
populations were defi ned from the ITT population 
(fi gure, appendix p 2). Notably, the ITT and modifi ed ITT 
populations were almost identical for effi  cacy assessment 
because no patient excluded from the modifi ed ITT 
population had data beyond week 8, which was the fi rst 
timepoint included for cumulative data analysis. 
Database lock was on Nov 24, 2015.
Baseline characteristics for the modifi ed ITT 
population are provided in table 1, and were similar for 
the ITT, per-protocol, and safety populations (data not 
shown). Mean exposure to masitinib in the modifi ed ITT 
population over the study duration was 18·9 (SD 22.0) 
months (range 0·1–74·1) versus 16·4 (19·3) months 
(0·7–72·3) for placebo. 
268 severe symptoms (pruritus, fl ushes, depression, 
and asthenia) were recorded at baseline in the modifi ed 
ITT population (136 in the masitinib group vs 132 in the 
placebo group). This number corresponds to a cumulative 
total of 1340 possible response evaluations for the 
primary analysis, indicating that the study was 
suffi  ciently powered. At baseline, severe pruritus was 
reported in about two thirds of patients from both 
treatment arms, severe fl ushes in about 27%, severe 
depression in about 39%, and severe asthenia in about 
75% (table 1).
At 24 weeks of treatment, masitinib was associated 
with a 4R75% of 18·7% versus 7·4% for placebo (odds 
ratio [OR] 3·6; 95% CI 1·2–10·8, p=0·0076; table 2). This 
positive outcome was verifi ed in the ITT population, as 
well as all predefi ned sensitivity analyses on the primary 
endpoint. Subgroup analysis in patients with KIT 
Asp816Val showed a signifi cant response in favour of 
masitinib, with a 4R75% of 20·2% (117·6 of 581·5) for 
masitinib versus 7·4% (42·8 of 581·5) for placebo 
(4·5; 1·1–17·8, p=0·0316) (appendix p 16). Subgroup 
analysis for other KIT cohorts was not possible owing to 
the small number of these patients. 
Masitinib (n=67) Placebo (n=62)
Demographic
Age (years) 45·3 (11·1; 19–69) 49·2 (12·7; 27–86)
Sex
Female 50/67 (75%) 41/62 (66%)
Male 17/67 (25%) 21/62 (34%)
c-KIT status 
Clonal (KIT Asp816Val) 63/67 (94%) 53/62 (86%)
KIT wild-type 1/67 (2%) 7/62 (11%)
Unknown 3/67 (5%) 2/62 (3%)
Disease type
Indolent systemic 
mastocytosis*
54/67 (81%) 49/62 (79%)
Smouldering systemic 
mastocytosis*
6/67 (9%) 7/62 (11%)
Unclassifi ed 7/67 (10%) 6/62 (10%)
Severe symptoms at baseline
Pruritus
Cases (%) 45/67 (67%) 42/62 (68%)
Mean score (SD) 9·0 (3·0) 9·1 (3·6)
Flushes
Cases (%) 18/66 (27%) 17/62 (27%)
Mean (SD) 8·0 (9·6) 6·4 (7·4)
Depression (HAMD-17)
Cases (%) 23/67 (34%) 27/62 (44%)
Mean score (SD) 16·0 (7·4) 17·3 (8·1)
Asthenia (FIS)
Cases (%) 50/66 (76%) 46/61 (75%)
Mean score (SD) 90·2 (37·1) 89·4 (34·3)
Objective marker of mast cell activation
Tryptase level (>20 μg/L)
Number of cases (%) 46/60 (77%) 44/62 (80%)
Mean (SD) 75·8 (120) 72·2 (75·6)
BSA urticaria pigmentosa† 87·8 (48·0) 101·0 (46·3)
Darier’s sign 21/25 (84%) 19/27 (70%)
Data are mean (SD; range) or n/number assessed (%) unless otherwise stated. 
HAMD-17=Hamilton Rating Scale for Depression. FIS=Fatigue Impact Scale. 
BSA=body surface area score corrected with Wallace formula. *Classifi cation 
according to investigator. †Systemic mastocytosis patients presenting with 
mastocytosis in the skin, specifi cally urticaria pigmentosa.
Table 1: Baseline characteristics according to the modifi ed intention-to-
treat population 
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We also noted improvement in secondary endpoints 
with masitinib (table 2). Endpoints representative of 
objective markers of mast cell activation were also 
positive (appendix p 11). At week 24, the mean change 
of tryptase level from baseline in the modifi ed ITT 
population was a decrease of 18·0% in the masitinib 
arm versus an increase of 2·2% in the placebo arm—
an absolute diff erence of 20·2% (p<0·0001). The 
response of urticaria pigmentosa lesions to masitinib 
diff ered when compared with placebo (p=0·0210) as 
evidenced by a decrease in average body surface area of 
12·3% for masitinib versus an increase of 15·9% for 
placebo—an absolute diff erence of 28·2%. The 
response to masitinib included one KIT Asp816Val-
positive patient who had a complete response at week 
24 (from baseline body surface area of 18%). This 
observation was supported by abolition of Darier’s sign 
in 18·9% of patients treated with masitinib versus 
2·7% treated with placebo—an absolute diff erence of 
16·2% (p=0·0187; appendix p 11).
Among patients entering the extension period, of 
whom 36 received masitinib treatment and 35 received 
placebo, a sustained response was observed in the 
masitinib group when compared with placebo for 
primary, secondary, and sensitivity outcomes (appendix 
p 11). 
Table 3 shows a summary of safety results during the 
24-week treatment period, regardless of causality. The 
most frequently occurring severe adverse events were 
diarrhoea (eight [11%] of 70 in the masitinib group vs one 
Masitinib Placebo Diff erence Odds ratio (95% CI) p value 
Primary outcome
4R75%
Modifi ed ITT (MDF) 122·6/656·5 (19%) 48·9/656·5 (7%) 11·2% 3·6 (1·2–10·8) 0·0076*
ITT 122·7/657·0 (19%) 49·8/657·0 (8%) 11·1% 3·3 (1·2–9·1) 0·0102
Modifi ed ITT (OC) 136·4/565·0 (24%) 44·4/565·0 (8%) 16·3% 4·9 (1·6–15·1) 0·0014
Per-protocol 125·8/626·5 (20%) 46·5/626·5 (7%) 12·7% 3·9 (1·3–11·5) 0·0048
Secondary outcomes
3R75%
Modifi ed ITT (MDF) 104·5/423·5 (25%) 41·5/423·5 (10%) 14·9% 3·1 (1·4–6·9) 0·0071
Modifi ed ITT (OC) 117·2/362·0 (32%) 37·5/362·0 (10%) 22·0% 4·1 (1·8–9·1) 0·0008
Per-protocol 107·0/403·5 (27%) 39·4/403·5 (10%) 16·8% 3·3 (1·5–7·5) 0·0038
2R75%
Modifi ed ITT (MDF) 81·9/301·5 (27%) 32·2/301·5 (11%) 16·5% 2·6 (1·1–6·6) 0·0380
Modifi ed ITT (OC) 92·2/254·5 (36%) 28·8/254·5 (11%) 24·9% 3·8 (1·5–9·4) 0·0042
Per-protocol 83·7/284·0 (29%) 30·3/284·0 (11%) 18·8% 2·9 (1·2–7·2) 0·0220
Pruritus
Modifi ed ITT (MDF) 47·1/214·5 (22%) 15·6/214·5 (7%) 14·7% 3·1 (1·1–8·9) 0·0322
Modifi ed ITT (OC) 53·0/178·5 (30%) 14·0/178·5 (8%) 21·8% 4·2 (1·5–12·0) 0·0071
Per-protocol 50·0/202·0 (25%) 14·7/202·0 (7%) 17·5% 3·7 (1·3–10·5) 0·0146
Flushes
Modifi ed ITT (MDF) 34·7/87·0 (40%) 16·6/87·0 (19%) 20·8% 3·0 (0·9–10·7) 0·09
Modifi ed ITT (OC) 39·3/76·0 (52%) 14·8/76·0 (20%) 33·3% 3·8 (1·1–13·8) 0·0402
Per-protocol 33·8/82·0 (41%) 15·6/82·0 (19%) 22·2% 3·1 (0·9–10·9) 0·09
HAMD-17
Modifi ed ITT (MDF) 22·7/122·0 (19%) 9·3/122·0 (8%) 11·0% 2·7 (0·7–11·1) 0·17
Modifi ed ITT (OC) 24·9/107·5 (23%) 8·7/107·5 (8·1%) 15·0% 3·3 (0·8–13·8) 0·10
Per-protocol 23·2/119·5 (19%) 9·1/119·5 (8%) 11·8% 2·9 (0·7–11·8) 0·14
FIS
Modifi ed ITT (MDF) 18·1/233·0 (8%) 7·4/233·0 (3%) 4·6% 4·8 (1·0–23·4) 0·0499
Modifi ed ITT (OC) 19·3/203·0 (10%) 6·9/203·0 (3%) 6·1% 7·0 (1·1–46·3) 0·0448
Per-protocol 18·8/223·0 (8%) 7·1/223·0 (3%) 5·2% 5·5 (1·1–27·4) 0·0370
Cumulative response based on generalised estimating equation (GEE) model, with missing data considered as failure (MDF), unless stated otherwise. Response rates 
expressed as weighted ratio of sum of actual responses between weeks 8 and 24 divided by the total number of possible responses over the same treatment period. Primary 
and secondary analyses were based on the modifi ed ITT (MDF) dataset. Sensitivity analyses were based on the ITT, modifi ed ITT (OC), and per-protocol datasets. 
4R75%=cumulative response in at least one of four severe baseline symptoms (pruritus, fl ushes, depression, or asthenia). ITT=intention-to-treat population. OC=observed 
cases dataset. 3R75%=cumulative response in at least one of three severe baseline symptoms (pruritus, fl ushes, or depression). 2R75%=cumulative response in at least one of 
two severe baseline symptoms (pruritus or fl ushes). HAMD-17=Hamilton Rating Scale for Depression. FIS=Fatigue Impact Scale. *Based on re-randomisation. 
Table 2: Effi  cacy results for primary, secondary, and sensitivity analyses, according to cumulative response analysis (weighted GEE model) 
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[2%] of 63 in the placebo group), rash (four [6%] vs none), 
asthenia (four [6%] vs one [2%]), peripheral oedema 
(two [3%] vs none), pruritus (three [4%] vs one [2%]), and 
neutropenia (three [4%] vs one [2%]; appendix p 13). The 
most frequent serious adverse events were diarrhoea 
(three patients [4%] vs one [2%]) and urticaria (two [3%] vs 
none; appendix p 13). No deaths were reported in the 
masitinib group, whereas one death, unrelated to study 
treatment, was reported in the placebo group. Overall, 
more adverse events occurred during the fi rst 6 months 
in the masitinib group than in the placebo group (table 3, 
appendix p 13).
Long-term safety over the extension period was 
assessed according to incidence per patient-months of 
exposure; this measure is more appropriate than 
frequency of adverse events given that some patients 
had been exposed to masitinib for over 2 years. This 
analysis revealed a comparable incidence of severe and 
serious adverse events between masitinib and placebo 
(table 4).
Discussion 
Treatment with masitinib resulted in a therapeutic benefi t 
across a diverse range of symptoms in patients with 
severely symptomatic indolent systemic masto cytosis 
who were unresponsive to optimal symptomatic 
treatments. Moreover, the response criterion of greater 
than 75% improvement in at least one severe baseline 
symptom constitutes a clinically meaningful eff ect, as 
evidenced by comparison with published recommendations 
on response evaluation.20 Data from the extension period 
showed that masitinib can maintain remission of 
symptoms for over 2 years; this is supported by results of 
the GEE model—a powerful tool for making statistical 
inference on longitudinal data.21 This observation is 
important, given that indolent systemic mastocytosis is a 
chronic condition that requires lifelong management. 
The primary analysis was supported by improvements 
seen in the predefi ned sensitivity analyses, notably the ITT 
population, and secondary analyses relating to patient-
reported symptomatic endpoints, as well as objective 
endpoints representative of mast cell activation (tryptase, 
Darier’s sign, and urticaria pigmentosa). Depression and 
asthenia are potential psychiatric manifestations of mast 
cell activation and can have a negative infl uence on the 
wellbeing of patients with systemic mastocytosis.1,2,22,23 
Thus, the improvement in endpoints, such as the Fatigue 
Impact Scale and Hamilton Rating Scale for Depression 
(non-signifi cant), and their associated 4R75% and 3R75% 
composite endpoints is indicative that masitinib can 
positively aff ect neuropsychiatric manifestations of 
systemic mastocytosis. These effi  cacy data confi rm 
observations from related phase 2 studies (appendix p 20).24
A common issue for clinical trials in orphan diseases is 
low sample number. In this study, we circumvented this 
problem by using the EMA-recommended repeated 
measures methodology.18 Despite the odds ratio 
confi dence intervals for primary and secondary endpoints 
being wide, a lower boundary of at least unity supports 
the superiority of masitinib over placebo. Use of a 
blinded central document reading introduced a risk of 
post-randomisation imbalance that was managed via 
weighting of each observation (appendix p 2). Sensitivity 
analyses that omitted the weighting function showed this 
process introduced negligible bias with closely matched 
data to the primary analysis (data not shown). Another 
complication for data interpretation arises because of the 
defi nition of indolent systemic mastocytosis used in this 
study is broader than the WHO classifi cation. Among 
the 135 patients with severe systemic mastocytosis 
according to the blinded central document reading, 
108 (80%) fulfi lled the criteria for WHO classifi cation of 
indolent systemic mastocytosis. Hence, 27 patients (20%) 
did not comply with the standard WHO classifi cation but 
were still eligible for inclusion in the ITT population 
according to the non-standard protocol defi nition of 
indolent systemic mastocytosis based on histological 
criteria of typical mast cell infi ltrates in a multifocal or 
diff use pattern in skin or bone marrow biopsy (appendix 
p 21). Finally, although protocol amendments made 
during the study to improve the benefi t–risk balance of 
the protocol are less than optimal, such changes did not 
bias the key fi ndings (appendix p 5). 
With regard to the mechanism of action, because the 
KIT Asp816Val mutation might not activate mast cells 
to release pro-infl ammatory mediators—which is 
consistent with clinical observations that type and 
severity of symptoms are KIT Asp816Val-independent—
the in activity of masitinib against this target is not 
necessarily a limitation.1,5,6,25 The treatment eff ect is 
hypothesised to be a result of masitinib targeting wild-
type mast cells, leading to a reduction in mast cell burden 
(an eff ect seen in long-term treatment of chronic myeloid 
leukaemia with the wild-type KIT-inhibitor imatinib; 
appendix p 17),26,27 or by reducing activation of KIT 
Asp816Val mast cells. The latter proposed mechanism is 
mediated through dual inhibition of LYN and FYN, 
which contribute to modulation of mast cell 
Masitinib (n=70) Placebo (n=63) Diff erence
At least one adverse event 70 (100%) 63 (100%) 0·0%
Death 0 1 (2%) −1·6%
Non-fatal serious adverse event 20 (29%) 12 (19%) 9·5% 
Severe adverse event 35 (50%) 22 (35%) 15·1%
Adverse event leading to permanent discontinuation 
(except death)
17 (24%) 4 (6%) 17·9%
In per-protocol population 12/62 (19%) 4/62 (6%) 12·9%
Adverse event leading to study treatment dose reduction 15 (21%) 1 (2%) 19·8%
Data are number of patients (%) aff ected. All data refer to safety population unless otherwise stated. For the 
per-protocol masitinib arm, fi ve patients were excluded owing to investigator non-compliance to predefi ned protocol 
safety rules regarding dose reduction. Adverse events reported according to any causality. Adverse event intensity 
count is cumulative.
Table 3: Safety summary over 24-week treatment period 
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degranulation in a KIT Asp816Val-independent manner.7 
The decrease we noted in mean tryptase levels in patients 
in the masitinib treatment arm is consistent with either 
of these eff ects—as are the individual decreases seen in 
most masitinib-treated patients (34 of 40, 85%; appendix 
pp 15–16). However, unknown factors could also 
contribute to these eff ects, as evidenced by the non-
universal patient susceptibility to masitinib, with 
identifi cation of predictive markers for patient treatment 
selection remaining a goal for future research. 
Masitinib was associated with increased frequency of 
adverse events during the fi rst 6 months of treatment 
compared with placebo, although no toxicities were life-
threatening, and over the long term (>1000 patient-
months) the incidence of adverse events was similar 
between masitinib and placebo. Toxicities were 
predominantly gastrointestinal or skin events, consistent 
with the known adverse-event profi le of masitinib, and 
which can be managed by dose reduction. Emerging 
evidence from the overall safety profi le of masitinib 
shows that a substantial improvement in tolerance of 
masitinib occurs after the initial 12-week treatment 
period (unpublished data). These toxicities could be 
mitigated via implementation of a dose-escalation 
scheme—eg, initial dose of 3·0 or 4·5 mg/kg per day 
with increments of 1·5 mg/kg per day every 4 weeks 
depending on absence of toxicity until reaching the target 
dose of 6 mg/kg per day. Nevertheless, the safety profi le 
of masitinib (including tolerance and toxicities) still 
compared favourably against that reported for interferon 
alfa, thalidomide, and cladribine—three drugs used in 
indolent mastocytosis. Treatment with interferon alfa has 
been associated with a variety of severe adverse events in 
almost every organ system, as well as with high levels of 
severe depression and severe cytopenia in patients with 
systemic mastocytosis.28,29 Use of thalidomide in patients 
with systemic mastocytosis is associated with severe 
peripheral neuropathy and severe myelosuppression.30 A 
retrospective study31 of 68 patients showed frequent 
severe (grade 3–4) adverse events with use of cladribine 
in mastocytosis, including lymphopenia, neutropenia, 
and opportunistic infections, of which one was fatal. 
Unlike aggressive forms of mastocytosis, indolent 
systemic mastocytosis—a rare condition with high, 
unmet medical need—has no registered or established 
standard treatment. Results from this study have shown 
a positive benefi t–risk ratio for masitinib in severely 
symptomatic patients with indolent systemic 
mastocytosis, including the subvariant of smouldering 
systemic mastocytosis, as evidenced by a sustained 
response and long-term incidence of adverse events 
that was equivalent to placebo. Masitinib might 
therefore be an important new treatment option for 
these patients; moreover, these data suggest a possibility 
for eff ective longer-term management of this diffi  cult-
to-treat disease.
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